Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

DAA Therapy for HCV & Recurrence of HCC

Gastroenterology; ePub 2019 Jan 18; Singal, et al

Direct-acting antiviral (DAA) therapy is not associated with increased overall or early hepatocellular carcinoma (HCC) recurrence, according to a large cohort of North American patients with complete response to HCC treatment. Researchers conducted a retrospective cohort study of patients with HCV-related HCC with a complete response to resection, local ablation, trans-arterial chemo- or radioembolization, or radiation therapy from January 2013 through December 2017 at 31 health systems throughout the US and Canada. They found:

  • Of 793 patients with HCV-associated HCC, 304 (38.3%) received DAA therapy and 489 (61.7%) were untreated.
  • HCC recurred in 128 DAA-treated patients (42.1%; early recurrence in 52 patients) and 288 untreated patients (58.9%; early recurrence in 277 patients).
  • DAA therapy was not associated with HCC recurrence (HR, 0.90) or early HCC recurrence (HR, 0.96), after adjustments.

Citation:

Singal AG, Rich NE, Mehta N, et al. Direct-acting antiviral therapy not associated with recurrence of hepatocellular carcinoma in a multicenter North American cohort study. [Published online ahead of print January 18, 2019]. Gastroenterology. doi:10.1053/j.gastro.2019.01.027.